Obstetrical & Gynecological Survey, 38(11), 643-646, 1983
Bromocriptine and premenstrual symptoms: a survey of double blind trials
Author affiliations
- Shanghai East Hospital ROR
Abstract
This is a survey of 14 placebo-controlled studies regarding the treatment of premenstrual symptoms with bromocriptine. There is no substantial support that bromocriptine is an effective drug in the premenstrual syndrome as an entity. Symptoms such as irritability, depression, and anxiety were not significantly improved during treatment with bromocriptine compared to placebo treatment. Bromocriptine appears to be the treatment of choice in premenstrual mastodynia if the dosage of bromocriptine is at least 5 mg daily. Bromocriptine may therefore have a place in selected cases of the premenstrual syndrome with associated mastodynia.
Topics
Cite this article
Andersch, B. (1983). Bromocriptine and premenstrual symptoms: a survey of double blind trials. *Obstetrical & gynecological survey*, *38*(11), 643-646. https://doi.org/10.1097/00006254-198311000-00001
Andersch B. Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet Gynecol Surv. 1983;38(11):643-646. doi:10.1097/00006254-198311000-00001
Andersch, B. "Bromocriptine and premenstrual symptoms: a survey of double blind trials." *Obstetrical & gynecological survey*, vol. 38, no. 11, 1983, pp. 643-646.
Keywords
Adult, Bromocriptine/therapeutic Use, Clinical Trials As Topic, Double-Blind Method, Female, Humans, Premenstrual Syndrome/diagnosis/drug Therapy, Bromocriptine